GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » Quick Ratio

RepliCel Life Sciences (RepliCel Life Sciences) Quick Ratio : 0.13 (As of Sep. 2023)


View and export this data going back to 2004. Start your Free Trial

What is RepliCel Life Sciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. RepliCel Life Sciences's quick ratio for the quarter that ended in Sep. 2023 was 0.13.

RepliCel Life Sciences has a quick ratio of 0.13. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for RepliCel Life Sciences's Quick Ratio or its related term are showing as below:

REPCF' s Quick Ratio Range Over the Past 10 Years
Min: 0.05   Med: 0.34   Max: 13.79
Current: 0.13

During the past 13 years, RepliCel Life Sciences's highest Quick Ratio was 13.79. The lowest was 0.05. And the median was 0.34.

REPCF's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.53 vs REPCF: 0.13

RepliCel Life Sciences Quick Ratio Historical Data

The historical data trend for RepliCel Life Sciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences Quick Ratio Chart

RepliCel Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.85 0.15 0.08 0.23 0.31

RepliCel Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.31 0.57 0.24 0.13

Competitive Comparison of RepliCel Life Sciences's Quick Ratio

For the Biotechnology subindustry, RepliCel Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RepliCel Life Sciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's Quick Ratio falls into.



RepliCel Life Sciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

RepliCel Life Sciences's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.468-0)/1.526
=0.31

RepliCel Life Sciences's Quick Ratio for the quarter that ended in Sep. 2023 is calculated as

Quick Ratio (Q: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.146-0)/1.12
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RepliCel Life Sciences  (OTCPK:REPCF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


RepliCel Life Sciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


RepliCel Life Sciences (RepliCel Life Sciences) Business Description

Traded in Other Exchanges
Address
570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.